<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Eflornithine (United States: Availability of intravenous preparation limited to CDC and WHO distribution programs) (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Eflornithine (United States: Availability of intravenous preparation limited to CDC and WHO distribution programs) (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Eflornithine (United States: Availability of intravenous preparation limited to CDC and WHO distribution programs) (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="143739" href="/d/html/143739.html" rel="external">see "Eflornithine (United States: Availability of intravenous preparation limited to CDC and WHO distribution programs) (systemic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="143706" href="/d/html/143706.html" rel="external">see "Eflornithine (United States: Availability of intravenous preparation limited to CDC and WHO distribution programs) (systemic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58946915"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Iwilfin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F58927920"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Ornithine Decarboxylase Inhibitor;</li>
<li>
                        Ornithine Decarboxylase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F58994749"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9620891e-d91b-4073-80a0-b2f9c15bd320">Neuroblastoma, high-risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma, high-risk (Iwilfin only): Note: </b>Recalculate the BSA dose every 3 months during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b></p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Recommended Eflornithine Dosage for Neuroblastoma According to BSA</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>BSA</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Eflornithine oral dosage </b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;1.5 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">768 mg twice daily; continue until disease recurrence, unacceptable toxicity, or a maximum of 2 years.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.75 m<sup>2</sup> to 1.5 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">576 mg twice daily; continue until disease recurrence, unacceptable toxicity, or a maximum of 2 years.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed doses: </i>
<b>Oral:</b> Administer the missed dose as soon as possible; if the next dose is due within 7 hours, the missed dose should be skipped. If vomiting occurs following administration, do not administer an additional dose; continue dosing with next scheduled dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b9a71f-ee84-41a5-b01f-1c2e2914ea2a">West African trypanosomiasis, second-stage disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>West African trypanosomiasis, second-stage disease (off-label use) (Ornidyl only):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in patients with second-stage infection with CNS involvement caused by <i>Trypanosoma brucei</i>
<i> gambiense</i> (West African)<i>.</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Combination therapy:</i>
<b>IV: </b>200 mg/kg every 12 hours for 7 days in combination with nifurtimox (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21628620','lexi-content-ref-19559476','lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21628620','lexi-content-ref-19559476','lexi-content-ref-WHO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Monotherapy (alternative therapy):</i>
<b>IV:</b> 100 mg/kg every 6 hours for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21628620','lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21628620','lexi-content-ref-WHO.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F58994751"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV</b>
<b>(off label): </b>No specific recommendations are available.</p></div>
<div class="block doha drugH1Div" id="F58994752"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to treatment initiation: </i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild hepatic impairment (bilirubin ≤ ULN and AST &gt; ULN <b>or</b> bilirubin &gt;1 times ULN and any AST): <b>Oral: </b>There are no dosage adjustments provided in the manufacturer's labeling; however, no clinically significant differences in eflornithine pharmacokinetics were noted based on mild hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe hepatic impairment: <b>Oral: </b>There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (off label):</b> No specific recommendations are available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Acute hepatotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">AST or ALT ≥10 times ULN: <b>Oral: </b>Withhold eflornithine until recovery to &lt;10 times ULN. If recovery occurs within 7 days of interruption, resume at the same dose. If recovery occurs after 7 days of interruption, resume at the next reduced dose level.</p></div>
<div class="block doo drugH1Div" id="F58994753"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma, high-risk:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F58994754"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Eflornithine Oral Dosage Reduction Levels</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Current eflornithine oral dosage</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Recommended eflornithine oral dosage and schedule for toxicity</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">768 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">576 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">576 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">384 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">384 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">192 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">192 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">192 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">192 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If unable to tolerate the minimum dose of 192 mg once daily, permanently discontinue eflornithine.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Eflornithine Oral Recommended Dosage Modifications for Adverse Reactions </b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Eflornithine oral dosage modification</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>Hematologic toxicity</b></p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Anemia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hemoglobin &lt;8 g/dL (first occurrence)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold eflornithine until hemoglobin ≥8 g/dL; resume eflornithine at the same dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hemoglobin &lt;8 g/dL (recurrent)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold eflornithine until hemoglobin ≥8 g/dL; resume eflornithine at the next reduced dose level.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neutropenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ANC &lt;500/mm<sup>3</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold eflornithine until ANC ≥500/mm<sup>3</sup>.</p>
<p style="text-indent:0em;text-align:left;">
<i>Recovery within 7 days of interruption:</i> Resume eflornithine at the same dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>Recovery after 7 days of interruption:</i> Resume eflornithine at the next reduced dose level.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Thrombocytopenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;25,000/mm<sup>3</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold eflornithine until platelets ≥25,000/mm<sup>3</sup>.</p>
<p style="text-indent:0em;text-align:left;">
<i>Recovery within 7 days of interruption:</i> Resume eflornithine at the same dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>Recovery within 7 to 14 days of interruption:</i> Resume eflornithine at the next reduced dose level.</p>
<p style="text-indent:0em;text-align:left;">
<i>Not recovered within 14 days of interruption</i>: Permanently discontinue eflornithine.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>Nonhematologic toxicity</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">GI toxicity (eg, nausea, vomiting, diarrhea)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If symptoms respond to supportive treatment (eg, anti-emetic or anti-diarrheal therapy), continue eflornithine at the same dose.</p>
<p style="text-indent:0em;text-align:left;">If symptoms do not respond to supportive treatment, withhold eflornithine until recovery to ≤ grade 2; resume eflornithine at the next reduced dose level.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ototoxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Clinically concerning new or worsening hearing loss compared to baseline audiogram</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Continue eflornithine dosing and repeat audiogram in 3 weeks.</p>
<p style="text-indent:0em;text-align:left;">
<i>Improvement on repeat audiogram:</i> Continue eflornithine at the same dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>Persistent clinically concerning changes on repeat audiogram: </i>Withhold eflornithine for up to 30 days and repeat audiogram.</p>
<p style="text-indent:0em;text-align:left;">If stable or improved, resume eflornithine at the next reduced dose level.</p>
<p style="text-indent:0em;text-align:left;">May also require hearing aids and/or eflornithine discontinuation based on severity.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Other adverse reactions</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold eflornithine until recovery to ≤ grade 2; resume eflornithine at the next reduced dose level.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4 (recurrent)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue eflornithine.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F58994750"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F59037385"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="143706" href="/d/html/143706.html" rel="external">see "Eflornithine (United States: Availability of intravenous preparation limited to CDC and WHO distribution programs) (systemic): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9620891e-d91b-4073-80a0-b2f9c15bd320">Neuroblastoma, high-risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma, high-risk: Note:</b> For use in patients who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥1 year and Adolescents: Iwilfin: <b>Note:</b> Recalculate BSA every 3 months and adjust dose accordingly.</p>
<p style="text-indent:-2em;margin-left:6em;">0.25 to &lt;0.5 m<sup>2</sup>: Oral: 192 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">0.5 to &lt;0.75 m<sup>2</sup>: Oral: 384 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">0.75 to ≤1.5 m<sup>2</sup>: Oral: 576 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;1.5 m<sup>2</sup>: Oral: 768 mg twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5a838e49-c795-4da9-9a2a-004ac6c67a77">
<i>Trypanosoma brucei gambiense</i> infection; second-stage infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Trypanosoma</i></b>
<b>
<i> brucei gambiense</i></b>
<b> infection (sleeping sickness</b>
<b>); second-stage infection: </b>Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-MSF.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-MSF.1'])">Ref</a></span>): <b>Note:</b> Parenteral product only available through special distribution programs; refer to <b>Prescribing Access</b> for additional information.</p>
<p style="text-indent:-2em;margin-left:4em;">NECT regimen: Children and Adolescents: IV: 200 mg/kg/dose every 12 hours for 7 days in combination with nifurtimox. NECT is the preferred regimen over monotherapy; it has been found to be safer, easier to administer and complete the course, and less expensive than eflornithine monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29471865']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29471865'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Monotherapy (difluoromethylornithine [DFMO]):</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;12 years: IV: 150 mg/kg/dose every 6 hours for 14 days.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: IV: 100 mg/kg/dose every 6 hours for 14 days.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Neuroblastoma; high-risk:</b> Children ≥1 year and Adolescents: Iwilfin: Oral: If an adverse reaction occurs, dose should be reduced based on current dose. If subsequent adverse reaction occurs, continue dose reductions until reaching the minimum dose; if patient is unable to tolerate the minimum dose then permanently discontinue therapy.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Dosage Adjustment for Eflornithine Tablets in Children ≥1 Year and Adolescents With Neuroblastoma</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Current oral daily dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Reduced oral dose for toxicity management</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">768 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">576 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">576 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">384 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">384 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">192 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">192 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">192 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">192 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue therapy if patient unable to tolerate dose.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Eflornithine Recommended Dosage Modifications for Adverse Reactions in Children ≥1 Year and Adolescents With Neuroblastoma </b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Eflornithine dosage modification</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>Hematologic toxicity</b></p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Anemia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hemoglobin &lt;8 g/dL (first occurrence)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold eflornithine until hemoglobin ≥8 g/dL; resume eflornithine at the same dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hemoglobin &lt;8 g/dL (recurrent)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold eflornithine until hemoglobin ≥8 g/dL; resume eflornithine at the next reduced dose level.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neutropenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ANC &lt;500/mm<sup>3</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold eflornithine until ANC ≥500/mm<sup>3</sup>.</p>
<p style="text-indent:0em;margin-top:2em;text-align:left;">
<i>Recovery within 7 days of interruption:</i> Resume eflornithine at the same dose.</p>
<p style="text-indent:0em;margin-top:2em;text-align:left;">
<i>Recovery after 7 days of interruption:</i> Resume eflornithine at the next reduced dose level.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Thrombocytopenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;25,000/mm<sup>3</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold eflornithine until platelets ≥25,000/mm<sup>3</sup>.</p>
<p style="text-indent:0em;margin-top:2em;text-align:left;">
<i>Recovery within 7 days of interruption:</i> Resume eflornithine at the same dose.</p>
<p style="text-indent:0em;margin-top:2em;text-align:left;">
<i>Recovery within 7 to 14 days of interruption:</i> Resume eflornithine at the next reduced dose level.</p>
<p style="text-indent:0em;margin-top:2em;text-align:left;">
<i>Not recovered within 14 days of interruption</i>: Permanently discontinue eflornithine.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>Nonhematologic toxicity</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">GI toxicity (eg, nausea, vomiting, diarrhea)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If symptoms respond to supportive treatment (eg, anti-emetic or anti-diarrheal therapy), continue eflornithine at the same dose.</p>
<p style="text-indent:0em;margin-top:2em;text-align:left;">If symptoms do not respond to supportive treatment, withhold eflornithine until recovery to ≤ grade 2; resume eflornithine at the next reduced dose level.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ototoxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Clinically concerning new or worsening hearing loss compared to baseline audiogram</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Continue eflornithine dosing and repeat audiogram in 3 weeks.</p>
<p style="text-indent:0em;margin-top:2em;text-align:left;">
<i>Improvement on repeat audiogram:</i> Continue eflornithine at the same dose.</p>
<p style="text-indent:0em;margin-top:2em;text-align:left;">
<i>Persistent clinically concerning changes on repeat audiogram: </i>Withhold eflornithine for up to 30 days and repeat audiogram.</p>
<p style="text-indent:0em;margin-top:2em;text-align:left;">If stable or improved, resume eflornithine at the next reduced dose level.</p>
<p style="text-indent:0em;margin-top:2em;text-align:left;">May also require hearing aids and/or eflornithine discontinuation based on severity.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Other adverse reactions</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold eflornithine until recovery to ≤ grade 2; resume eflornithine at the next reduced dose level.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4 (recurrent)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue eflornithine.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F59037429"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥1 year and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Neuroblastoma:</b> Oral: Iwilfin: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Trypanosoma brucei gambiense</i> infection (sleeping sickness):</b> IV: Dose should be adjusted although no specific guidelines are available.</p></div>
<div class="block dohp drugH1Div" id="F59037430"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma:</b> Oral: Iwilfin:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥1 year and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Baseline hepatic impairment: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Mild hepatic impairment (bilirubin ≤ ULN and AST &gt; ULN <b>or</b> bilirubin &gt;1 times ULN and any AST): Oral: There are no dosage adjustments provided in the manufacturer's labeling; however, no clinically significant differences in eflornithine pharmacokinetics were noted based on mild hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:8em;">Moderate to severe hepatic impairment: Oral: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Acute hepatotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT ≥10 times ULN: Oral: Withhold eflornithine until recovery to &lt;10 times ULN. If recovery occurs within 7 days of interruption, resume at the same dose. If recovery occurs after 7 days of interruption, resume at the next reduced dose level.</p>
<table border="1" frame="border" rules="all" style="margin-left:10em;">
<caption style="text-align:left;">
<b>Dosage Adjustment for Eflornithine Tablets in Children ≥1 Year and Adolescents With Neuroblastoma</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Current oral daily dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Reduced oral dose for toxicity management</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">768 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">576 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">576 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">384 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">384 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">192 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">192 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">192 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">192 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue therapy if patient unable to tolerate dose.</p></td></tr></tbody></table></div>
<div class="block adr drugH1Div" id="F58965284"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported for the oral formulation in children and adolescents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (15%; grade 3: 4%), vomiting (11%; grade 3: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis media (32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Allergic rhinitis (11%), cough (15%), pneumonia (12%), sinusitis (13%), upper respiratory tract infection (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (&lt;5%), skin infection (7%), skin rash (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum glucose (2%), decreased serum potassium (2%), decreased serum sodium (2%), increased serum glucose (1%), increased serum potassium (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (5%; grade 3: 2%), decreased neutrophils (9%; grades 3/4: 8%), decreased platelet count (1%), decreased white blood cell count (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (9%), increased serum alkaline phosphatase (5%), increased serum aspartate aminotransferase (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss (7%)</p></div>
<div class="block coi drugH1Div" id="F58927865"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F58994730"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Grades 3 or 4 elevations of AST, ALT, and bilirubin have been observed in patients treated with eflornithine, leading to dosage modification or discontinuation in a small percentage of patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myelosuppression: Eflornithine may cause myelosuppression, including grade 3 anemia, grades 3 or 4 neutropenia, and grades 3 or 4 thrombocytopenia. Febrile neutropenia and bone marrow failure occurred rarely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ototoxicity: Eflornithine may cause hearing loss. In the clinical study, more than three-quarters of treated patients had an abnormal audiogram at baseline, with new or worsening hearing loss occurring in 12% of patients (including worsening to grades 3 or 4 hearing loss and tinnitus in one patient). New or worsening hearing loss during treatment with eflornithine led to new hearing aid use, dosage modifications, and dosage discontinuation in some patients. Among all patients that experienced hearing loss with eflornithine, ~10% resolved to baseline, and of those who had dosage modification, approximately two-thirds of patients improved or had resolution to baseline.</p></div>
<div class="block foc drugH1Div" id="F58946916"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Iwilfin: 192 mg [contains corn starch]</p></div>
<div class="block geq drugH1Div" id="F58946914"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F59040197"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Iwilfin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">192 mg (per each): $108.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F58994712"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">
<i>Eflornithine IV (off label):</i> Injectable eflornithine is donated to the World Health Organization (WHO) by the manufacturer. In the United States, eflornithine injection is available through the CDC for treatment of second-stage African trypanosomiasis (caused by <i>Trypanosoma brucei gambiense</i>) with CNS involvement. Further information may be found on the WHO website at https://www.who.int/health-topics/human-african-trypanosomiasis or by contacting the CDC Drug Service (404-639-3670). Additional information from the CDC is available at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Flaboratory%2Fdrugservice%2Fformulary.html&amp;token=8fUMx%2BfB4trlY8x%2FMo8Y9Ddj5kItZ1H7qlW%2Fe3GJptY28xGubTU0DXWzUi5nl8%2BCwNhzfAcY95p7Mq5fGdd6Fg%3D%3D&amp;TOPIC_ID=143704" target="_blank">https://www.cdc.gov/laboratory/drugservice/formulary.html</a>.</p></div>
<div class="block adm drugH1Div" id="F58994755"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with or without food; tablets may be swallowed whole, chewed, or crushed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Crushed tablets preparation:</i> For patients with difficulty swallowing tablets, eflornithine may be chewed, or crushed and mixed with 2 tablespoons of soft food or liquid. Visually confirm the entire contents of the dose are administered; if crushed tablet particles remain, may mix with an additional small volume (eg, no more than 1 ounce [30 mL]) of soft food or liquid. Discard crushed preparation if not administered within 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV</b>
<b>(off label): </b>Administer IV only; do <b>not</b> administer IM. Dilute prior to use and infuse over 120 minutes; replace IV catheter at least every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19559476','lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19559476','lexi-content-ref-WHO.1'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F59037432"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with or without food; tablets may be swallowed whole, chewed, or crushed. If dose is vomited, an additional dose should not be administered; continue with next scheduled dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Crushed tablets preparation</i>: For patients with difficulty swallowing tablets, eflornithine may be chewed, or crushed and mixed with 2 tablespoons of soft food or liquid. Visually confirm the entire contents of the dose are administered; if crushed tablet particles remain, may mix with an additional small volume (eg, no more than 1 ounce [30 mL]) of soft food or liquid. Discard crushed preparation if not administered within 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Administer diluted solution by IV infusion over 120 minutes; not for IM administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-MSF.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-MSF.2'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F58994732"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Eflornithine may cause developmental toxicity.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NIOSH.1','lexi-content-ref-USP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NIOSH.1','lexi-content-ref-USP.1'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USP.1'])">Ref</a></span>). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F58927864"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Neuroblastoma, high-risk:</b> To reduce the risk of relapse of high-risk neuroblastoma in adult and pediatric patients who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy (Iwilfin tablets only).</p></div>
<div class="block off-label drugH1Div" id="F58994719"><span class="drugH1">Use: Off-Label: Adult</span><p>West African trypanosomiasis, second-stage disease</p></div>
<div class="block mst drugH1Div" id="F58994710"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F58968851"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F58968848"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F58994722"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to initiating treatment in patients who could become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who may become pregnant should use effective contraception during therapy and for 1 week after the last dose of eflornithine. Patients with partners who could become pregnant should also use effective contraception during therapy and for 1 week after the last eflornithine dose.</p></div>
<div class="block pri drugH1Div" id="F58994723"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to eflornithine may cause fetal harm. Embryolethality was observed following oral administration to pregnant rats and rabbits during the period of organogenesis with doses equivalent to the recommended human dose (based on BSA).</p>
<p style="text-indent:0em;margin-top:2em;">Limited outcome data related to systemic eflornithine in pregnancy are available following use as part of combination therapy for the treatment of West African trypanosomiasis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34748572','lexi-content-ref-23209861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34748572','lexi-content-ref-23209861'])">Ref</a></span>).</p></div>
<div class="block brc drugH1Div" id="F58994724"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if eflornithine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 1 week after the last dose of eflornithine.</p>
<p style="text-indent:-2em;margin-left:2em;">Limited outcome data related to systemic eflornithine in breastfeeding patients are available following use as part of combination therapy for the treatment of West African trypanosomiasis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34748572','lexi-content-ref-23209861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34748572','lexi-content-ref-23209861'])">Ref</a></span>).</p></div>
<div class="block mop drugH1Div" id="F58994758"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Monitor CBC (prior to therapy and periodically during treatment); liver function (ALT, AST, and total bilirubin) tests (prior to therapy, every month for the first 6 months of treatment, then every 3 months or as clinically indicated; monitor more frequently in patients with transaminase or bilirubin elevations). Obtain baseline audiogram; repeat audiogram at 6-month intervals or as clinically indicated to monitor hearing loss. Verify pregnancy status prior to initiating treatment in patients who could become pregnant. Monitor for signs/symptoms of hepatotoxicity and hearing loss. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:4em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32716741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32716741'])">Ref</a></span>) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV (off label):</b> CBC with platelet counts. Monitor for signs/symptoms of hearing loss.</p></div>
<div class="block pha drugH1Div" id="F58994743"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Eflornithine exerts antitumor and antiprotozoal effects through specific, irreversible inhibition of the enzyme ornithine decarboxylase (ODC). ODC is the rate-limiting enzyme in the biosynthesis of polyamines in nucleated cells. Polyamines are necessary for the synthesis of DNA, RNA, and proteins and are, therefore, necessary for cell growth and differentiation. Mammalian cells depend on ornithine decarboxylase to produce polyamines.</p>
<p style="text-indent:-2em;margin-left:2em;">In the treatment of neuroblastoma, ODC inhibition by eflornithine additionally reverses the effects of the LIN28/Let7 metabolic pathway (involved in cancer stem cell regulation and glycolytic metabolism), decreasing expression of oncogenic drivers MYCN and LIN28B (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37883734','lexi-content-ref-30262852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37883734','lexi-content-ref-30262852'])">Ref</a></span>). In vitro, eflornithine suppressed neurosphere formation in neuroblastoma cell lines, regardless of MYCN amplification (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30262852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30262852'])">Ref</a></span>).</p></div>
<div class="block phk drugH1Div" id="F58994744"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Oral: V<sub>d</sub>: 24.3 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Oral: 3.5 hours; IV (off label): 1.5 to 5 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19559476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19559476'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Oral: 3.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: Oral: 5.3 L/hour.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control (CDC). CDC Infectious Diseases Laboratories: Our Formulary. <a href="https://www.cdc.gov/laboratory/drugservice/formulary.html" target="_blank">https://www.cdc.gov/laboratory/drugservice/formulary.html</a>. Last reviewed May 18, 2018. Accessed January 23, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-systemic-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-systemic-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Iwilfin.1">
<a name="Iwilfin.1"></a>Iwilfin (eflornithine) [prescribing information]. Louisville, KY: USWM, LLC; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29471865">
<a name="29471865"></a>Kansiime F, Adibaku S, Wamboga C, et al. A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda. <i>Parasit Vectors</i>. 2018;11(1):105. doi:10.1186/s13071-018-2634-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-systemic-drug-information/abstract-text/29471865/pubmed" id="29471865" target="_blank">29471865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21628620">
<a name="21628620"></a>Kappagoda S, Singh U, Blackburn BG. Antiparasitic therapy. <i>Mayo Clin Proc</i>. 2011;86(6):561-583. doi:10.4065/mcp.2011.0203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-systemic-drug-information/abstract-text/21628620/pubmed" id="21628620" target="_blank">21628620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34748572">
<a name="34748572"></a>Kuemmerle A, Schmid C, Bernhard S, et al. Effectiveness of nifurtimox eflornithine combination therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: report from a field study. <i>PLoS Negl Trop Dis</i>. 2021;15(11):e0009903. doi:10.1371/journal.pntd.0009903<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-systemic-drug-information/abstract-text/34748572/pubmed" id="34748572" target="_blank">34748572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MSF.1">
<a name="MSF.1"></a>Medecins Sans Frontieres (MSF). Clinical guidelines. Diagnosis and treatment manual for curative programmes in hospitals and dispensaries. Guidance for prescribing, 2018 edition.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MSF.2">
<a name="MSF.2"></a>Medecins Sans Frontieres (MSF). Essential drugs: practical guide intended for physicians, pharmacists, nurses and medical auxiliaries, 2016 edition.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1355219">
<a name="1355219"></a>Milord F, Pépin J, Loko L, Ethier L, Mpia B. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. <i>Lancet</i>. 1992;340(8820):652-655. doi:10.1016/0140-6736(92)92180-n<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-systemic-drug-information/abstract-text/1355219/pubmed" id="1355219" target="_blank">1355219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37883734">
<a name="37883734"></a>Oesterheld J, Ferguson W, Kraveka JM, et al. Eflornithine as postimmunotherapy maintenance in high-risk neuroblastoma: externally controlled, propensity score-matched survival outcome comparisons. <i>J Clin Oncol</i>. 2024;42(1):90-102. doi:10.1200/JCO.22.02875<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-systemic-drug-information/abstract-text/37883734/pubmed" id="37883734" target="_blank">37883734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19559476">
<a name="19559476"></a>Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomized, phase III, non-inferiority trial. <i>Lancet</i>. 2009;374(9683):56-64. doi: 10.1016/S0140-6736(09)61117-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-systemic-drug-information/abstract-text/19559476/pubmed" id="19559476" target="_blank">19559476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23209861">
<a name="23209861"></a>Schmid C, Kuemmerle A, Blum J, et al. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness. <i>PLoS Negl Trop Dis</i>. 2012;6(11):e1920. doi:10.1371/journal.pntd.0001920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-systemic-drug-information/abstract-text/23209861/pubmed" id="23209861" target="_blank">23209861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30262852">
<a name="30262852"></a>Sholler GLS, Ferguson W, Bergendahl G, et al. Maintenance DFMO increases survival in high risk neuroblastoma. <i>Sci Rep</i>. 2018;8(1):14445. doi:10.1038/s41598-018-32659-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-systemic-drug-information/abstract-text/30262852/pubmed" id="30262852" target="_blank">30262852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20219092">
<a name="20219092"></a>Steverding D. The development of drugs for treatment of sleeping sickness: a historical review. <i>Parasit Vectors</i>. 2010;3(1):15. doi:10.1186/1756-3305-3-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-systemic-drug-information/abstract-text/20219092/pubmed" id="20219092" target="_blank">20219092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed December 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). WHO interim guidelines for the treatment of gambiense human African trypanosomiasis. Geneva: World Health Organization; 2019. https://www.who.int/publications/i/item/9789241550567.</div>
</li></ol></div><div id="topicVersionRevision">Topic 143704 Version 13.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
